Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center

We studied on a large group, and these significant findings may have important implications for the investigation, pathogenesis, and treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: The aim of the study is to describe the clinical characteristics of Antineutrophil cytoplasmic antibodies-associated vasculitis and to analyze the parameters affecting the outcome.

📊

Key Findings & Data:Totally 130 patients with Antineutrophil cytoplasmic antibodies-associated vasculitis (18 years and over) who were followed up between October 2014 and October 2019 were analyzed.

💡

Conclusion & Impact:We studied on a large group, and these significant findings may have important implications for the investigation, pathogenesis, and treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis.

🔬Design:Review & Systematic Survey

📍Scope:2014 Verileri

⚙️Variables:Domain Parameters

Özet

Objective: The aim of the study is to describe the clinical characteristics of Antineutrophil cytoplasmic antibodies-associated vasculitis and to analyze the parameters affecting the outcome. Materials and Methods: The study is a retrospective cohort study. Totally 130 patients with Antineutrophil cytoplasmic antibodies-associated vasculitis (18 years and over) who were followed up between October 2014 and October 2019 were analyzed. Demographic data, laboratory values, clinical course, thorax computed tomography findings and treatment approaches were noted from the charts of patients. Patients were divided into two groups as those with pulmonary involvement and non-pulmonary involvement. Results: We retrospectively reviewed the medical records of 130 patients with Antineutrophil cytoplasmic antibodies-associated vasculitis; 111 with granulomatosis with polyangiitis, 15 with microscopic polyangiitis, 1 with eosinophilic granulomatosis with polyangiitis, and 3 with other types of vasculitis. The ratio of having the abnormality in thoracic computed tomography was 72.2%. There were 84 cases with pulmonary involvement and 46 cases with non-pulmonary involvement. The frequency of microscopic polyangiitis was significantly higher (p=0.034) in non-pulmonary involvement cases. There were 67 cases with proteinase 3 Antineutrophil cytoplasmic antibodies and 39 cases with myeloperoxidase Antineutrophil cytoplasmic antibodies positivity. Most of the cases with proteinase 3 Antineutrophil cytoplasmic antibodies positivity were classified as granulomatosis with polyangiitis, this was statistically significant. Recovery was referenced for the outcome. Any of the variables were found statistically significant effective on outcome. Conclusions: Cases with pulmonary involvement were more than the cases without pulmonary involvement in our study. microscopic polyangiitis was significantly higher in non- pulmonary involvement cases. We studied on a large group, and these significant findings may have important implications for the investigation, pathogenesis, and treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis.

🔖

Cite This Article

IRMAK, İ., BAŞ, S., İNAM, M. G., TEKİN, F., YEŞİLYURT, B., BİLGİN, A. E., KILIÇ, L., KARADAĞ, Ö., ÇÖPLÜ, L. (2020). Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center. Acta Medica, Cilt: 51 - Sayı: 4, 22–32. https://ajindex.com/articles/205839

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (15)

Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013; 65: 1-11
Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum.1999; 42(3): 421-430
Lane SE, Watts RA, Shepstone L, et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98(2): 97-111
Frankel SK, Schwarz MI. The pulmonary vasculitides. Am J Respir Crit Care Med. 2012; 186(3): 216-224
Alba MA, Flores-Suárez LF, Henderson AG, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017; 16(7): 722-729
Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009; 68(12): 1827-1832
Hervier B, Pagnoux C, Agard C, et al. French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis. 2009; 68(3): 404-407
Ananthakrishnan L, Sharma N, Kanne JP. Wegener’s granulomatosis in the chest: high-resolution CT findings. Am J Roentgenol. 2009; 192(13): 676-682
Lohrmann C, Uhl M, Kotter E, et al. Pulmonary manifestations of Wegener granulomatosis: CT findings in 57 patients and a review of the literature. Eur J Radiol. 2005; 53(3): 471-477
Pretorius ES, Stone JH, Hellman DB, et al. Wegener’s Granulomatosis: CT evolution of pulmonary parenchymal findings in treated disease. Crit Rev Comput Tomogr. 2004; 45(1): 67-85
Ando Y, Okada F, Matsumoto S, et al. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr. 2004; 28(5): 710-716
Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM. 1997; 90(6): 391-399
Mohammad AJ, Bakoush O, Sturfelt G, et al. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol. 2009; 38(4): 268-275
Travis WD, Leslie KO, Beasley MB. Pulmonary vasculitis and pulmonary hemorrhage. In: Leslie KO, Wick MR. Practical pulmonary pathology: a diagnostic approach. Philadelphia (PA): Elsevier; 2018; 365-400
Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fi